X0508 4 2023-10-19 0 0001827506 Tourmaline Bio, Inc. TRML 0001569226 Srivastava Sapna C/O TOURMALINE BIO, INC. 27 WEST 24TH STREET, SUITE 702 NEW YORK NY 10010 1 0 0 0 0 Common Stock 2023-10-19 4 A 0 518 A 518 D Stock Option (Right to Buy) 2.54 2023-10-19 4 D 0 20500 0.00 D 2033-06-13 Common Stock 20500 0 D Stock Option (Right to Buy 9.46 2023-10-23 4 A 0 20000 0.00 A 2033-10-22 Common Stock 20000 20000 D Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 22, 2023, by and among Tourmaline Bio, Inc., the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer, the Reporting Person's stock option to purchase 20,500 shares of Common Stock of the Issuer (prior to giving effect to the reverse stock split described below) was accelerated and cancelled at the effective time of the merger contemplated by the Merger Agreement. In consideration for such cancellation, the Reporting Person received a cash payment of $8,066 and 518 shares of Common Stock (after giving effect to a 10-for-1 reverse stock split of the Issuer's Common Stock effected immediately prior to the effective time of the merger). The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. The shares subject to the option vest in substantially equal monthly installments over a three-year period measured from one month following October 23, 2023, subject to the Reporting Person's continued service on each such vesting date. /s/ Brad Middlekauff, Attorney-in-Fact 2023-10-23